Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088512 · Präparat HOS-083663
Drugs by Therapeutic Area
Interaction Recommendation
Geometric mean change (%) concerning co-
(Possible mechanism) administration
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Didanosine /Zidovudine Interaction not studied.
Stavudine/Lamivudine Interaction not studied. Combination not
Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended.
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Lamivudine Interaction not studied. As only limited data available
Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is
(750 mg twice daily with Atovaquone AUC unknown.
food/200 mg thrice daily)
Clarithromycin/Lamivudine Interaction not studied. Separate administration of
Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin
(500 mg twice daily/100 mg by at least 2 hours
every 4 hours)
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage
(Co-trimoxazole)/Lamivudine adjustment necessary, unless
(160 mg/800 mg once daily for Trimethoprim: AUC patient has renal impairment
5 days/300 mg single dose) Sulfamethoxazole: AUC (See Section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) stavudine (HOS-088080) atovaquone (HOS-086266) clarithromycin (HOS-084517) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage ef0dd78ec8fb1f808137e8f5128b1cd7fa4540efa9cc39a15103836ffbdd97d9 · Zeichen 1146–3116 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088513 · Präparat HOS-083663
(organic cation transporter When concomitant
inhibition) administration with co-
Trimethoprim/sulfamethoxazole Interaction not studied. trimoxazole is warranted,
(Co-trimoxazole)/Zidovudine patients should be monitored
clinically. High doses of
trimethoprim/
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage a5b5ecc033f9627aa4197b73f6ecfc4795888cbbf3b59b8698319c08ba2953d6 · Zeichen 3149–3685 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) fluconazole (HOS-087945) phenobarbital (HOS-085617) phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-108561 · Präparat HOS-093047
8
Stavudine/Zidovudine In vitro antagonism of anti-HIV
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Abacavir Interaction not studied. As only limited data available
Atovaquone/Lamivudine Interaction not studied. the clinical significance is
Atovaquone/Zidovudine Zidovudine AUC 33% unknown.
(750 mg twice daily with Atovaquone AUC
food/200 mg thrice daily)
Clarithromycin/Abacavir Interaction not studied. Separate administration of
Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by
Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours
(500 mg twice daily/100 mg
every 4 hours)
Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment
(Co-trimoxazole)/Abacavir necessary, unless patient has
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section
(Co-trimoxazole)/Lamivudine 4.2).
(160mg/800mg once daily for 5 Trimethoprim: AUC
days/300mg single dose) Sulfamethoxazole: AUC When concomitant
administration with co-
(organic cation transporter trimoxazole is warranted,
inhibition) patients should be monitored
Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of
(Co-trimoxazole)/Zidovudine trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) stavudine (HOS-088080) atovaquone (HOS-086266) clarithromycin (HOS-084517) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 71bfdfc92b9301a18965d48965dbae21382ab47ace7b98ce7ba0a04318a98c78 · Zeichen 2506–4852 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113477 · Präparat HOS-093937
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine /Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Zidovudine/Abacavir Interaction not studied
Zidovudine/Lamivudine Lamivudine: AUC
Zidovudine 300 mg single dose Zidovudine : AUC
Lamivudine 150 mg single dose
Emtricitabine/Lamivudine Due to similarities, Kivexa
should not be administered
concomitantly with other
cytidine analogues, such as
emtricitabine.
ANTI-INFECTIVE PRODUCTS
Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment
(Co-trimoxazole)/Abacavir necessary.
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40%
(Co-trimoxazole)/Lamivudine When concomitant
(160 mg/800 mg once daily for Trimethoprim: AUC administration with
5 days/300 mg single dose) Sulfamethoxazole: AUC co-trimoxazole is warranted,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.